NewEdge Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

NewEdge Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,500	Closed	-$19.4K	–	4321
2025 Q3	$19.4K	Buy	+11,500	New	+$13.6K	﹤0.01%	3134
2023 Q2	–	Sell	-12	Closed	-$18	–	3576
2023 Q1	$18	Hold	12	–	–	﹤0.01%	3388
2022 Q4	$0	Buy	+12	New	+$15	﹤0.01%	4159
2020 Q1	–	Sell	-10,000	Closed	-$8K	–	850
2019 Q4	$8K	Hold	10,000	–	–	﹤0.01%	813
2019 Q3	$10K	Sell	10,000 -7	-0.1%	-$7	﹤0.01%	810
2019 Q2	$11K	Buy	10,007 +7	+0.1%	+$8	﹤0.01%	653
2019 Q1	$13K	Hold	10,000	–	–	﹤0.01%	669
2018 Q4	$9	Sell	10,000 -24,290	-71%	-$37.2K	﹤0.01%	624
2018 Q3	$71K	Buy	34,290 +11,430	+50%	+$24K	0.01%	642
2018 Q2	$41	Sell	22,860 -5,410	-19%	-$10.9K	﹤0.01%	537
2018 Q1	$64K	Buy	28,270 +10,771	+62%	+$25.3K	0.01%	484
2017 Q4	$42K	Buy	+17,499	New	+$38.2K	0.01%	405

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NewEdge Advisors's LCTX Position: Q4 2025 in Review

NewEdge Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q4 2025, closing a stake of 11,500 shares — an estimated $19.4K sold.

NewEdge Advisors first reported a position in LCTX in Q4 2017 and held it in 12 quarters. The position peaked at $71K in Q3 2018. 123 funds tracked by Wall St. Rank hold LCTX as of Q4 2025.

NewEdge Advisors reported no remaining Lineage Cell Therapeutics position as of Q4 2025 after selling out during the quarter.
NewEdge Advisors sold 11,500 Lineage Cell Therapeutics shares in Q4 2025, an estimated $19.4K.
NewEdge Advisors first reported a position in Lineage Cell Therapeutics in Q4 2017 and held it in 12 quarters.
NewEdge Advisors's Lineage Cell Therapeutics position peaked at $71K in Q3 2018.
123 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.